



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jill Giles-Komar et al

Serial No.: 10/720,323

Art Unit:

: November 24, 2003

Examiner:

Filed

For

INTEGRIN : ANTI-DUAL

ANTIBODIES.

COMPOSITIONS,

METHODS AND USES.

I hereby certify that this correspondence is being deposited with the lited States Postal Service so first class small in an envelope addressed to: Commissioner For Patants, P. O. Box 1450 on

2004 APRIL 15. (Date of Deposit)

KENNETH J.

2004 APRIL 15,

(Date of Signature)

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. \$\$1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☑ In accordance with §1.97(b), since this Information isclosure Statement is being filed either within three months if the filing date of the above-identified national application other than a continued prosecution application under [1.53(d)], within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a the mailing date of a first Office Action after the filing of a
the mailing date of a first office had a said an additional
request for continued examination under §1.114, no additional
fee is required.
☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore: ☐ Statement in Accordance with §1.97(e)
☐ In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: ☐ Statement in Accordance with \$1.97(e) (attached); or

please charge Deposit Account No. 10-
0750/CEN249CIPNP/KD the fee of \$180.00 as set
4.5
101411
☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p). ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
attached Form PIO-1445 are onto
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
∑ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner from the Patent Application SN09/920,267, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
$\hfill\Box$ There are no listed references which are not in the English language.
The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN249CIPNP/KD. This form is submitted in triplicate. Respectfully submitted, Renneth J. Dow Reg. No. 32,890 Attorney for Applicants
Johnson & Johnson Plaza

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 651-7422 DATED: APRIL 1**5**, 2004

PTO/SB/08A (08-00) PTO/SB08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

U.S. Patent and Trademark Unice, U.S. and to a collection of information unless it dis-	plays a valid OM8 control number.
Application Number	
Filing Date	November 24, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 249 CIPNP
Attorney ===	

Examiner Initials		U.S. Patent Documen		Name of Patentee or Applicant	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	Cite No.1	Number	(ind Code ² (if known)	of Cited Document		
	No.		T	Yuan-Po Tu et al	10-07-1997	
	-	5,674,483	+	Francesc Mitjans et al	11-16-1999	
	1	5,985,278	-	Kyung Jin Kim et al	04-09-2002	
	<u> </u>	6,369,204	A1	Kyung Jin Kim et al	03-19-2002	
6,359,126 6,171,588 2001/0011125 5,753,230		6,359,126	A1	Christopher P. Carron et al	01-09-2001	
	6,171,588	B1		08-02-2001		
			A1	William D. Huse	05-19-1998	
	1			Brooks et al		
	\top					
			1			

				FO	REIGN PATENT DOCUMENTS	Date of Publication	Pages, Columns, Lines, where relevant	1
		Foreign F	Patent Docume	nt	Name of Patentee or	of Cited Document mm-dd-yyyy	passages or relevant figures appear	T°
Examiner	Cite	Office ³	office ³ Number ⁴ KindCode ⁵		Applicant of Cited Document		ligates appoin	+-
Initials	No.1	0		TA	Smithkline Beecham Corp.	06-02-2000		┰
		wo	0031248	+	Children's Hospital	08-03-2000		+
		wo	0044404	A		09-28-1995		L
		wo	95/25543	A1	Scripps Research Institute			
	+-	wo	97/06791	A1	Scripps Research Institute	02-27-1997		T
	↓	+	-	A1	G. D. Searle & Co.	10-09-1997		+
	WO 9//36659 A.		10-14-1993		-			
		wo	93/20229	A1	Genentech, Inc.	07-03-1996		1
	+-	EPO	719859	A1	Merck Patent GMBH	07-03-1880		

	-			Date	
Everniner				Considered	it are alterior if not in conformance and not
Signature		to the control citation is in confo	rmance with MF	PEP 609. Dra	w line through citation if not in conformance and not
*EXAMINER: Initial if	reference of	considered, whether of flot citation to applicant.			

considered. Include copy of this form with next communication to applicant.

1.Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WPO Standard ST3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIFO Standard ST, 16 if possible, a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is essimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Officer, U. S. Patent and Trademark Officer, Washington, on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Officer, U. S. Patent and Trademark Officer, Washington, on the property of the Chief information Officer, U. S. Patent and Trademark Officer, U. S. Patent and Trademark Officer, Washington, on the Chief information Officer, U. S. Patent and Trademark Officer, U. S. Paten



FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450. istant Commissioner for Patents, Alexandria, VA 22313-1450.
PTO/SR094A (09-00)
Approved for use through 10/31/2002. OM8 0551-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	to necessary and the necessary	and to a collection of Information unless it disp	2,000
	Under the Paperwork Reduction Act of 1995, no persons are required to resp	Application Number	10/720,323
	Under the Paperwork recosors	Application Number	November 24, 2
Substitute for form	n 1449A/PTO	Etter Date	November 24, 2
Substitute for for		Filling Date	Jill Giles-Komar
	RMATION DISCLOSURE	First Named Inventor	JIII CITED TROTTE
	NAATION DISCLUSURE	7 // 51 / 10 / 10	1
INFO	KIVIA I ION BIOGET	Group Art Unit	
	EMENT BY APPLICANT		
OT A T	CMENT RY APPLICANT	Examiner Name	CEN 249 CIPN
SIAI	EMENI DI VIII	Attorney Docket Number	CEN 245 OII 11

(use as many sheets as necessary)

2003 Examiner Name CEN 249 CIPNP Attorney Docket Number

	U.S. Patent Doo		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
Cite No. ¹	Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant rigures appoin
_					
-					
-					
+					-
			-		
		Cite		Cite Kind Code of Cited Document	Cite Kind Code of Cited Document of Cited Document mm-dd-yyyy

					REIGN PATENT DOCUMENTS	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant										
Examiner Initials		Foreign Patent Document			Name of Patentee or	mm-dd-yyyy	passages or relevant figures appear	T ⁶									
	Cite No.1	-	-	Number ⁴	KindCode ⁵	Applicant of Cited Document	06/09/1994										
	No.															94/12181 A1 Merck & Co., Inc.	Merck & Co., Inc.
		wo	94/12101	+				+-									
	l							1									
	1			1				1									
	+	┼						\top									
				+-				+-									
		1															
	-					-		1									
			-	_		1		4									

- 1		Date	
	Examiner Signature *EXAMINER: Initial if reterence considered, whether or not citation is in conformance with	Considered	the state explormance and not
	Examiner	MPEP 609 Dra	aw line through citation if not in consorting.
	Signature Signat	WIF ET GOOT ET	
	*EXAMINER: Initial if reference considered, which next communication to applicant.		

considered. Include copy of this form with next communication to applicant. Unique citation designation number, a See attached Kinds of U.S. Patent Documents, a Enter Office that issued the document, by the two-letter L'Unique citation designation number, à See attached Kinds of U.S. Patent Documents, à s'rac' Ormos trait issued me document, by the two-site code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precéde the serfal number of the patent document Standard ST.3 in a fundament of the patent document standard ST.3 in a fundament of the patent document standard ST.3 in a fundament of the patent document standard ST.3 in a fundament standard ST.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. CMB 0651-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

nd to a collection of information unless it dis	plays a valid OMB control number.
Application Number	
Application Number	November 24, 2003
Filing Date	Jill Giles-Komar
First Named Inventor	
Group Art Unit	
Examiner Name	CEN 249 CIPNP
Attorney Docket Number	CEN 243 O

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), tille of the article (when appropriate), tille of the riccie (when appropriate), tille of the article (when appropriate), tille of the article (when appropriate) are its common continuous and appropriate (in the common continuous appropriate).	
	-	OTHER PRIOR ART - NON LETTERS), title of the article (when appropriate), title of the order	T ²
		heating pame of the author (in CAPITOL LETTER actions etc.) date, page(s), volume-issue humber(s).	- 1
		(book, magazine, journal, serial, symposium, catalog, etc.), date, peg- publisher, city and/or country where published published affinity and functional blockade of glycoprotein	-
Examiner's Initials'	Cite		- 1
	No.1	A Sabalyimah (ReoPro, Chimeric 7E3 Fab) Demonstrator 1091 USA	
		TAM et al. "Abclimate (ReoPro, Chimeric PES Fab) Demonstrames - 1091, U.SA. Borlla and o.g. het heterorie v. or 88, bit. 10, 10, 10, 10, 10, 10, 10, 10, 10, 10,	
		hibritia and cubs more place and the American Association for Cancer Research, 1997.	- 1
		TRIKH's et al., and an	
	1	and alpha/usage 377, USA. March 2000, Page 377, USA. March 2000, Page 377, USA. SUZUKI et al., "CDNA and amino acid sequences of the cell adhesion profein receptor," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, "Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, "Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, "Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, "Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors," Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, "Cell Biology, November 1986, pages 8614- transmentrane domain and homologies with other adhesion profein receptors, and the profein	
		March 2000, page 3 "cCNA and amino acid sequences of the cell attribute." Cell Biology, November 1986, pages 30	
	1	SUZUN et al. When an experiment of the properties of the properti	
	1	transmential & Proc. National Academy Science, USA.	
		8618, vol. 83. Proc. National Academic Analysis and easiers to Reconciler and Detroit St. U.S.A. LEHMANN ET Al., "A monosciler analysis in a facility of the Control Research, 1996, pegas 27 250.A. ESERIHARD ST. VIS. St. C. R. C. Carper Research, 1996, pegas 27 250.A. ESERIHARD GUNSILUS, CLEMENS (SOUTHER CASE). C. C. R. C.	
	1	LEHIMANING THE INTEGRAL OF S. α.β.ς. CANCER HESCHILL, 155-15-15-15-15-15-15-15-15-15-15-15-15-	
		recognizes the integrine cyte,	
		GUNTHER AND ANDREA KRAFT, "Angiogenesis as a target of clobary integrins during angiogenesis: insignis 102 pp. 9	
	1	BRIAN F. Edition and clinical development. The JOSEPH M. SHAFFER, CHRISTINE M. KINCAID, JULY VINTEGRINS.	
		UNGER, AND DAVID A. CHERESH, "The role of aphral magnition, May 1999, 1227-30, vol. 103, 103. BRIAN P. ELICIERI AND DAVID A. CHERESH, "The role of aphral magnition, May 1999, 1227-30, vol. 103, 103. BRIAN P. ELICIERI AND	
	1	MARTIN FRIEDDANDERSH, "DEFINITION OF TWO ANGIOGENIN PATH IN THE AND	
		AND DAVID A. 1985. 1500-2. vol. 270. Segindo, Diec. 1985. 1500-2. Segindo, Diec. 198	
		Sedence, USE. OF CONTROL E CARMACK DENNIS HUSZAR, KYR IX. O'DONNELL, ROBERT M. KAY, OLLYE USA D. TAYLOR OF CARMACK CHINAGO CHI KUO, SUSAN L. O'DONNELL, ROBERT M. KAY, OLLYE SECURIAR, STEPHEN R. SCHRAMA, CHINAGO CHI KUO, SUSAN L. O'DONNELL, ROBERT M. KAY, OLLYE WOODHOUSE, AND HILLS LONGE MIS HUMBAI Immunication systems under control of the control	
	1	SCHAR STEPHEN R. SCHRAMM, CHIUNG-United Intranspense undergo rearrangement, some A Oxford University	
	1	WOODHOUSE, AND NILS LONGERG, "Human influencing influencings, 1994; 579-91, Vol. 6 No. 4, October 1994; 1994	
	1	LISA D. TAYLOW R. SCHRAMM, CHUNG-CHI KUO, SUS-AV. undergo rearrangement, somatic mutuation and SCOLAR, STEPHEN R. SCHRAMM, CHUNG-CHI Kuong minumoglobulin transpense undergo rearrangement, somatic mutuation WOODHOUSE, NIO BLANCHERS, Tuman minumoglobulin transpense undergo rearrangement, somatic mutuation WOODHOUSE, NIO BLANCHERS, CHING MINUMOGLOBULING, STEPHEN R. STEPHE	
		WOODHOUSE, you mine that lack endogenous lgM, international immunous lack of the class switching in mine that lack endogenous lgM, international immunous lack of the class of	
		Press. NILS IONBERG, USA D. TAYLOR, FIONA A. HAPUNING, MATHEMYN WYMORE, JAMÉS G. MUCKO, ROSHANKA MASHAYEN, G. LAPACHET, TASH BENOGECHEA, DIANNE M. SCHRAMM, CHUNG-GH, KUO, ROSHANKA MASHAYEN, G. LAPACHET, TASH BENOGECHEA, DIANNE M. MUNICZ/PREMNIE P. CARMACK, ROBERT M. KAY AND CENNIS HUSZAP. "Antigen-specific human ambodies from MUNICZ/PREMNIE" F. CARMACK, ROBERT M. KAY AND CENNIS HUSZAP. "Antigen-specific human ambodies from MUNICZ/PREMNIE" F. CARMACK, ROBERT M. KAY AND CENNIS HUSZAP. "Antigen-specific human ambodies from MUNICZ/PREMNIE" F. CARMACK, ROBERT M. KAY AND CENNIS HUSZAP. "Antigen-specific human ambodies from MUNICZ/PREMNIE" F. CARMACK, ROBERT M. KAY AND CENNIS HUGG, SEG. 1998. 1999. 1999. 1999.	
	1	NILS LONBERG, LINC, FILOSHANAK, MASHAYERY, M. LAPACHET, TASH BERNOCECHEA, DIANNE, INSCHAMM, CHIN, SUBAN, L. D'CONNELL, ELIZABETH S. MUNOZO-FRESHAN, DIANNE, INSCHAMON, AND SENSON	
	- 1	MINOZ-O'REGAN, SUSAN L O'DONNET M KAY AND DENNIS HUSZAR, "ARREST-SPECIAL	
1	- 1	FISHWILD, CONDIE E. CARMACK, HODERS Nature, April 28, 1994, 856-9, vol. 368.	
	١	MUNOZ-O REGAN. SUSAN TANDERT M. KAY AND DENNIS VANDER SESSE VIOL 369. RISHMILD, CONDIE E CARMACK, ROBERT M. KAY AND DENNIS VANDER SESSE VIOL 369. RISH CONDIE E CARMACK, ROBERT M. KAY AND SENSE SESSE VIOL 369. RISHMILD, CONDIE E CARMACK, ROBERT M. KAY KAY M. HIGGINS, STEPHEN R. SCHRAMM, AND NILS LONBERG, DIANE M. RISHMILD, SUSAN L. DOLANE M. KAY, KAY M. HIGGINS, STEPHEN R. SCHRAMM, AND NILS LONBERG. DENSE MORE SESSE VANDER SESSE VAN	
		mich compression and the properties of the prope	1
		DIANNE M. FISHWILD, SUSAN L. O'DUNIELL, MAY KAY M. HIGGINS, STEPHEN H. SCHOOLS transperie mice," Nature	1
	- 1	MICHAEL NEUBERIUS SUSAN L OTOŚNIELI. TASH BENOUSEZINEN R SCHRAMM, AND NILS LUNBERGY. DIANNE M FISHERIES LONGER, ROBERT M KY, KAY M. HIGGINS, STEPHEN R SCHRAMM, AND NILS LUNBERGY. L BERNHARD, DONNER, ROBERT M KY, KAY M. HIGGINS, STEPHEN R SCHRAMM, AND NILS LUNBERGY. Nature of the Company	-
	- 1	High-avidity human IgG-kappa monocurial anadous	1
	- 1	"High-avidity numan" 1995, 845-51, vol. 14. Biotechnology, July 1995, 845-51, vol. 14. Biotechnology, July 1995, 845-51, vol. 14.	1
			_
	- 1	High-worldy nutries as 5.51 vol. 14 Biotermoday, vol. 1982, 5.551 vol. 14 ElizaBETH A WANNER, DOBERT A ORLANDO AND DAVID A. CHEREST, integrins sibila v beta 3 and alpha v beta 5 ELIZABETH A WANNER, DOBERT A ORLANDO AND DAVID A. CHEREST, integrins sibila v beta 3 or display of the Contribute to cell Attachment to Visconscein but Differentially Distribute on the Cell Surface, "J. Cell Biology, May 1911, 1916 Owner, March 1918, 1918, 1918 Owner, MARCH 1918, 1918 Own	1
	- 1	29, vol. 113, no. 4 and acts with alpha 5 beta 1 to	1
		JOHN F. MARSHALL, DEBOHAH C. w bata 1 is a receptor for vitronectin and fibrillogen, and	-
	- 1	Conflibide to Cear Auditations: 29 vt. 113, 703. 29 vt. 113, 703. 20 vt. 113, 703	1
	- 1	OPHY AND IAN F. HART, "Alpha vetal 1 is a receptor 23, vot. 108. OCC box operating on formerin", "J. Cell Secretaria 1990, 1992, vot. 108. OCC box operating on formerin", "J. Cell Secretaria 1990, 1992, vot. 109. ONID A. CHERISH AND ROBERT C. Cell Attachment to Vitionectin, Phonocena, and von Willebrand Factor," J. Ord Natachment to Vitionectin, Phonocena, and von Willebrand Factor, "Old Receptor invoked in Human Nationary 1992, vot.	1
	-	DAVID A. CHERESH AND HOLLOWING Cell Attachment to Vitronectin, Hipringen, and Volume	+-
B		Receptor involved in Human Metal 17703-11, vol. 262, no. 36.	1
B	- 1	Biological Chemistry, Dec. 23 1907. By WILINANDS, AND ED ROOS, "Alpha v integration of alpha v beta 5 is Codistributed will	١١
1	-+	DAVID A. CHEMEST AND MELANDRA CEIL Attachment to Virotrecuit, vincined to the Company of the Com	+-
N	- 1	HANS KEMPEHANAY, Adhelon DeTrorrection is Mediated Solely by Small Amounts of alpha votes in votes in Amounts of Percentage in the Percentage in Amounts of Section 1997, 1997	21
ll .	- 1	Actin Fibers, Experimental CHANTAL BABENANDRASANA, RICHARD TAMOHA, Unhibits Adhesion to Fibronectic	. 1
-	-	MAXIME LEHMANN, CHANTA AND JACQUES MARVALDI, "A Monocornal reliable to be a 3, alpha v beta 5, and alpha	٧ ١
N .	١.		+-
ii .	- 1	Addit Destriction Control Transport of the Con	-
N	- 1	beta 6:, Cancer neseason, cyr.	-+-
-	$\neg \neg$		+
-	_		
-	-		+-
1			+
	-+		
 	-+		
1	-+		
-	-		
L			